Clinical Trial of SAHA in Patients With Breast Cancer
Status:
Unknown status
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Purpose:
- evaluate the safety of Vorinostat.
- evaluate the effectiveness of Vorinostat in treating breast cancer
- evaluate how the study subject's body reacts to Vorinostat, how these reactions relate
to the subject's genes, and whether protein changes in the subject blood may be used to
predict how the subject's cancer will respond to Vorinostat
We hypothesize that Vorinostat, as a novel class of anti-cancer agents, may induce response
in patients with recurrent or metastatic breast cancer who have been previously treated with
anthracyclines and taxanes. In addition, we hypothesize that serum Vorinostat levels may
correlate with clinical response and toxicities, and that Vorinostat may induce unique
protein changes in the plasma in responding patients, and that these proteins may in turn be
used as predictive biomarkers for treatment response.